ALNYLAM PHARMACEUTICALS, INC. Total Assets

• ALNYLAM PHARMACEUTICALS, INC. showed an increase of +17.1% in Total Assets from 2024 to 2025.
• This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: $440.18 million | Q3 2010: $412.61 million | Q1 2011: $369.05 million | Q2 2011: $340.83 million | Q3 2011: $310.22 million | Q1 2012: $340.30 million | Q2 2012: $318.48 million | Q3 2012: $322.35 million | Q1 2013: $471.58 million | Q2 2013: $462.56 million | Q3 2013: $447.50 million | Q1 2014: $1.08 billion | Q2 2014: $1.03 billion | Q3 2014: $986.36 million | Q1 2015: $1.63 billion | Q2 2015: $1.53 billion | Q3 2015: $1.44 billion | Q1 2016: $1.32 billion | Q2 2016: $1.38 billion | Q3 2016: $1.31 billion | Q1 2017: $1.13 billion | Q2 2017: $1.43 billion | Q3 2017: $1.36 billion | Q1 2018: $1.92 billion | Q2 2018: $1.79 billion | Q3 2018: $1.68 billion | Q1 2019: $2.01 billion | Q2 2019: $2.72 billion | Q3 2019: $2.54 billion | Q1 2020: $2.28 billion | Q2 2020: $3.37 billion | Q3 2020: $3.31 billion | Q1 2021: $3.26 billion | Q2 2021: $3.51 billion | Q3 2021: $3.47 billion | Q1 2022: $3.43 billion | Q2 2022: $3.33 billion | Q3 2022: $3.54 billion | Q1 2023: $3.39 billion | Q2 2023: $3.40 billion | Q3 2023: $3.84 billion | Q1 2024: $3.82 billion | Q2 2024: $4.01 billion | Q3 2024: $4.21 billion | Q1 2025: $4.21 billion | Q2 2025: $4.57 billion | Q3 2025: $4.85 billion.
• Over the full 17 years of available data (2009 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Total Assets has grown by 931.7%.
• Historical annual values: Fiscal year 2025: $4.97 billion | Fiscal year 2024: $4.24 billion | Fiscal year 2023: $3.83 billion | Fiscal year 2022: $3.55 billion | Fiscal year 2021: $3.64 billion | Fiscal year 2020: $3.41 billion | Fiscal year 2019: $2.40 billion | Fiscal year 2018: $1.57 billion | Fiscal year 2017: $1.99 billion | Fiscal year 2016: $1.26 billion | Fiscal year 2015: $1.39 billion | Fiscal year 2014: $1.08 billion | Fiscal year 2013: $420.53 million | Fiscal year 2012: $287.52 million | Fiscal year 2011: $281.92 million | Fiscal year 2010: $393.27 million | Fiscal year 2009: $481.39 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026